J

James E. Dahlman

Georgia Institute of Technology

ORCID: 0000-0001-7580-436X

Publishes on RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques, CRISPR and Genetic Engineering. 124 papers and 13.1k citations.

124Publications
13.1kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Emerging Frontiers in Drug Delivery
Mark W. Tibbitt, James E. Dahlman, Róbert Langer|Journal of the American Chemical Society|2016
Cited by 959

Medicine relies on the use of pharmacologically active agents (drugs) to manage and treat disease. However, drugs are not inherently effective; the benefit of a drug is directly related to the manner by which it is administered or delivered. Drug delivery can affect drug pharmacokinetics, absorption, distribution, metabolism, duration of therapeutic effect, excretion, and toxicity. As new therapeutics (e.g., biologics) are being developed, there is an accompanying need for improved chemistries and materials to deliver them to the target site in the body, at a therapeutic concentration, and for the required period of time. In this Perspective, we provide an historical overview of drug delivery and controlled release followed by highlights of four emerging areas in the field of drug delivery: systemic RNA delivery, drug delivery for localized therapy, oral drug delivery systems, and biologic drug delivery systems. In each case, we present the barriers to effective drug delivery as well as chemical and materials advances that are enabling the field to overcome these hurdles for clinical impact.